The immunogenicity of modified lipoproteins

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 367-378

  Lopes Virella, Maria F ^a,b,d   Thorpe, Suzanne R ^c   Derrick, M Brooks ^a,b   Chassereau, Charlyne ^a,b   Virella, Gabriel ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Strom Thurmond Research Building ^*  (United States)

Author keywords

AGE LDL; Anti lipoprotein antibodies; Atherosclerosis; Autoimmunity; Diabetes; Diabetic complications; Inflammation; Maillard reaction; Modified lipoproteins

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MACROGOL; MALONALDEHYDE;

AFFINITY CHROMATOGRAPHY; ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD SAMPLING; CONFERENCE PAPER; DIABETES MELLITUS; ENZYME IMMUNOASSAY; GLYCATION; HUMAN; HUMAN CELL; IMMUNE COMPLEX DISEASE; IMMUNOGENICITY; INFLAMMATION; LIPOPROTEIN METABOLISM; PROTEIN LIPID INTERACTION; PROTEIN MODIFICATION; SUPERNATANT;

ANIMALIA;

EID: 23744465627     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.043     Document Type: Conference Paper

References (37)

1. STEINBRECHER, U.P. 1987. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262: 3603-3608.
2. STEINBERG, D. 1988. Metabolism of lipoproteins and their role in pathogenesis of atherosclerosis. Atherosclerosis Rev. 18: 1-23.
3. YLA-HERTTUALA, S. et al. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84: 1086-1095.
4. PALINSKI, W. et al. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
5. REQUENA, J.R. et al. 1997. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins. Biochem. J. 322: 317-325.
6. SCHMIDT, A.M. et al. 1995. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96: 1395-1403.
7. IKEDA, K. et al. 1998. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J. Immunol. Methods 215: 95-104.
8. ONORATO, J.M., S.R. THORPE & J.W. BAYNES. 1998. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N.Y. Acad. Sci. 854: 277-290.
9. NAKAMURA, Y. et al. 1993. Immunochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes melitus. Am. J. Pathol. 143: 1649-1656.
10. PALINSKI, W. et al. 1995. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler. Thromb. Vasc. Biol. 15: 571-582.
11. VIRELLA, G. & M.F. LOPES-VIRELLA. 2003. Lipoprotein autoantibodies: measurement and significance. Clin. Diag. Lab. Immunol. 10: 499-505.
12. MIRONOVA, M., G. VIRELLA & M.F. LOPES-VIRELLA. 1996. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler. Thromb. Vasc. Biol. 16: 222-229.
13. VIRELLA, G. et al. 2000. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 95: 135-144.
14. VIRELLA, G. et al. 2003. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 443: 487-493.
15. PALINSKI, W. et al. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98: 800-814.
16. LOPES-VIRELLA, M.F. & G. VIRELLA. 2003. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front. Biosci. 8: s750-s768.
17. VIRELLA, G. & M. F. LOPES-VIRELLA. 2003. Humoral immunity and atherosclerosis. Nat. Med. 9: 243-244.
18. VIRELLA, G. et al. 2004. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Res. 45: 1859-1867.
19. HOLVOET, P. et al. 1998. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18: 100-107.
20. ITABE, H. et al. 1996. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37: 45-53.
21. YAMAZAKI, K. et al. 2004. Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Atherosclerosis 172: 181-187.
22. TOSHIMA, S. et al. 2000. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 2243-2247.
23. BOULLIER, A. et al. 2000. Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty. Clin. Chim. Acta 299: 129-140.
24. FESTA, A. et al. 1998. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41: 350-356.
25. LOPES-VIRELLA, M.F. et al. 1999. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90: 165-172.
26. MIRONOVA, M. et al. 1997. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85: 73-82.
27. OREKHOV, A.N. et al. 1991. Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13: 233-236.
28. VIRELLA, G. et al. 1979. Nephelometric detection of soluble immune complexes: methodology and clinical applications. Internat. Arch. Allergy Appl. Immunol. 58: 402-410.
29. VIRELLA, G. et al. 1981. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia 21: 184-191.
30. ATCHLEY, D.H. et al. 2002. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45: 1562-1571.
31. LOPES-VIRELLA, M.F. 2001. Diabetes and atherosclerosis. In Diabetes and Cardiovascular Disease. M.T. Johnstone & A. Veves, Eds.: 169-194. Humana Press. Totowa, NJ.
32. YANG, C.Y. et al. 1999. Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. J. Lipid Res. 40: 686-698.
33. VIRELLA, G. & G. TSOKOS. 2001. Immune complex diseases. In Medical Immunology. G. Virella, Ed.: 453-471. Marcel Dekker. New York.
34. OREKHOV, A.N. et al. 1991. Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13: 233-236.
35. ORCHARD, T.J. et al. 1999. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48: 1454-1458.
36. LOPES-VIRELLA, M.F. et al. Modified lipoprotein-immune complexes and progression of internal carotid intima-media thickness in type 1 diabetes. Submitted.
37. KOSKINEN, S. et al. 1998. Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin. Diag. Lab. Immunol. 5: 817-822.